DEBORAH GREENGRASS: Open Payments
NPI 1134288491 · WEST ORANGE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$699 in 33 payments from 11 companies in 2025. Trend: 2023 $152 · 2024 $429 · 2025 $699
Food & beverage: $614Education: $85
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 7 | $201 |
| AstraZeneca Pharmaceuticals LP | 8 | $145 |
| Merck Sharp & Dohme LLC | 4 | $81 |
| Caris MPI, Inc. | 3 | $73 |
| Tempus AI, Inc | 2 | $42 |
| GlaxoSmithKline, LLC. | 2 | $38 |
| ABBVIE INC. | 2 | $34 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Verastem, Inc. | 1 | $20 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $18 |
Products named: LYNPARZA, Veozah, MI CANCER SEEK, KEYTRUDA, XT CDX, JEMPERLI, ELAHERE, MYFEMBREE.
Industry payments across NJ — which companies pay providers there.
